AAAAAA

   
Results: 1-11 |
Results: 11

Authors: Egg, R Reindl, M Deisenhammer, F Linington, C Berger, T
Citation: R. Egg et al., Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis, MULT SCLER, 7(5), 2001, pp. 285-289

Authors: Deisenhammer, F Reindl, M Berger, T
Citation: F. Deisenhammer et al., Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against TFN-beta 1b, J INTERF CY, 21(3), 2001, pp. 167-171

Authors: Reindl, M Knipping, G Wicher, I Dilitz, E Egg, R Deisenhammer, F Berger, T
Citation: M. Reindl et al., Increased intrathecal production of apolipoprotein D in multiple sclerosis, J NEUROIMM, 119(2), 2001, pp. 327-332

Authors: Buttner, U Chofflon, M Hess, K Kappos, L Kesselring, J Ludin, HP Schluep, M Vaney, C Baumhackl, U Berger, T Deisenhammer, F Freimuller, M Hartung, HP Kollegger, H Kristoferitsch, W Lassmann, H Markut, H Vass, K Altenkirch, H Boese, J Gass, A Gehlen, W Goebels, N Haas, J Haferkamp, G Heidenreich, F Heitmann, R Hemmer, B Hohlfeld, R Janzen, RWC Jugelt, E Kolmel, W Konig, N Kowitzsch, K Manegold, U Melms, A Mertin, J Petereit, HF Pette, M Pohlau, D Poser, S Sailer, M Schmidt, S Schock, G Schulz, M Seidel, D Stangel, M Stark, E Stoll, G Weinrich, W Wietholter, H Zettl, UK Zipp, F Zschenderlein, R Bayas, A Chan, A Flachenecker, P Gold, R Grauer, O Jung, S Kallmann, B Leussink, V Maurer, M Rieckmann, P Toyka, KV Weilbach, FX
Citation: U. Buttner et al., Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement, NERVENARZT, 72(2), 2001, pp. 150-157

Authors: Stockhammer, G Poewe, W Burgstaller, S Deisenhammer, F Muigg, A Kiechl, S Schmutzhard, E Maier, H Felber, S Schumacher, P Gunsilius, E Gastl, G
Citation: G. Stockhammer et al., Vascular endothelial growth factor in CSF - A biological marker for carcinomatous meningitis, NEUROLOGY, 54(8), 2000, pp. 1670-1675

Authors: Deisenhammer, F Mayringer, I Harvey, J Dilitz, E Gasse, T Stadlbauer, D Reindl, M Berger, T
Citation: F. Deisenhammer et al., A comparative study of the relative bioavailability of different interferon beta preparations, NEUROLOGY, 54(11), 2000, pp. 2055-2060

Authors: Kiechl, S Willeit, J Deisenhammer, F Poewe, W
Citation: S. Kiechl et al., Sensory predominant neuropathy with GM(1) antibodies, conduction blocks, and orbital pseudotumour, J NE NE PSY, 68(2), 2000, pp. 252-253

Authors: Deisenhammer, F Fazekas, F Strasser-Fuchs, S Nahler, G Mamoli, B
Citation: F. Deisenhammer et al., Intravenous immunoglobulins in multiple sclerosis: Results of the Austrianimmunoglobulin in multiple sclerosis (AIMS) trial, INFUSIONSTH, 26, 1999, pp. 42-47

Authors: Kaser, A Deisenhammer, F Berger, T Tilg, H
Citation: A. Kaser et al., Interferon-beta(1b) augments activation-induced T-cell death in multiple sclerosis patients, LANCET, 353(9162), 1999, pp. 1413-1414

Authors: Deisenhammer, F Reindl, M Harvey, J Gasse, T Dilitz, E Berger, T
Citation: F. Deisenhammer et al., Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies, NEUROLOGY, 52(6), 1999, pp. 1239-1243

Authors: Reindl, M Linington, C Brehm, U Egg, R Dilitz, E Deisenhammer, F Poewe, W Berger, T
Citation: M. Reindl et al., Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study, BRAIN, 122, 1999, pp. 2047-2056
Risultati: 1-11 |